Хелпикс

Главная

Контакты

Случайная статья





И. П. ЛАПИН 15 страница



Нуллер Ю. Л., Лапин И. П. Влияние характера информации о препа­рате на эффективность пацебо и мепробамата // Клин. мед. 1971. № 9. С. 139-144.

Нуллер Ю. Л., Михаленко И. Н. Аффективные психозы. Л.: Медици­на, 1988. 264 с.

ОСухов Я. Л. Синий цвет // Журн. практического психолога. 1997. № 1. С. 30-41.

Орликов А. Б. Сравнительное исследование эффективности имипрами-на, диазепама, баклофена, пропранолола и плацебо у больных с па­ническим расстройством // Обозрение психитрии и медицинской психологии. 1994. № 4. С. 43-50.

Прозоровский В. Б. Почему лекарства лечат. Л.: Лениздат. 1991. 190 с.

Рубитель А. В., Набокова А. И., Лапин И. П. Цвет лекарства и ожи­даемое его психотропное действие // Индивидуализация и оцен­ка эффективности психофармакотерапии: Сб. науч. тр. Ленин-градск. научно-исследовательского психоневрологическ. института им. В. М. Бехтерева, 1987. Т. 117. С. 49-54.

Рысс Е. С, Щерба Н. Н., Соловьева С. Л. Роль нарушения эмоциональ­ных связей в развитии язвенной болезни // Клин. мед. 1985. № 9. С. 74-78.

Серов Н. Б. Лечение цветом. Мода и гармония. СПб.: Лисе, 1993. 47 с.

Темков И„ Киров К. Клинична психофармакология. 2-е изд. София: Медицина, 1976. 334 с.

Темков И., Шойлекова М. Въерху проблема за т. нар. индиректен пла­цебо ефект // Неврология, психиатрия, неврохирургия. София, 1976. Т. 15. Бр. 5. С. 320-326.

Узнадзе Д. Я. Экспериментальные основы психологии установки. Тби­лиси: Изд-во ТГУ, 1961. 210 с.

Фулфорд К. У. М., Хаус К. Этика научных исследований с вовлечени­ем психиатрических пациентов: принципы, проблемы и ответствен­ность ученых // Соц. и клин, психиатрия. 1997. Т. 7. Вып. 4. С. 84-93.

Хайкин Р. Б. Художественное творчество глазами врача. СПб.: Наука, 1992. 231 с.

Хаунина Р. А., Лапин И. П. Применение фенибута в психоневрологии и его место среди других психотропных средств // Журн. невропа-тол. и психиатр. 1989. Т. 89. № 4. С. 142-151.

Часар Г. Проблема плацебо // Венгерская фармакотерапия. 1981. № 4. С. 139-144.

Яновски К., Еже П., Бигус С, Герес Е. Новые точки зрения в проблема­тике плацебо // Medicamentum: Информация для врачей и фарма­цевтов. 1989. Bd. 29, № 1. S. 23-25; № 4. S. 119-122; 1990. Bd. 30. Jvfs 1. S. 53-56.

Achtee К. Psychosocial factors in a doctor's work // Pscyhiatria fennica.

1983. V. 14. P. 59-67. Adam K. et al. Do placebo alter sleep? // Brit. Med. J. 1976, Jan. 24. V. 1

(6003). P. 195-196. Addington D. et al. Placebos in clinical trials of psychotropic medication //

Canadian J. of Psychiatry. 1997. V. 42. No. 3. P. 6. Albert L. H.. Goldstein A. Partial antagonism of placebo analgesia by

naloxone // Pain. 1983. V. 16. No. 2. P. 129-143. Alvar-ez-Patino L. M., Cortes Sotres J. F. Attitude of psychiatric patients

toward the anxiety and depression psychotropic drugs. CINP/CMNP

Regional Meeting. Abstracts. 1997. P. 66. Anderson R J., Lynne M. K. Methods of improving patient compliance in

chronic disease states // Arch. Int. Med. 1982. V. 142. P. 1673-1677. Appelbaum P. S., Roth L. H. Patients who refuse treatment in medical hos­pitals // JAMA. 1983. V. 250. P. 1296-1298.

Литература                                                             209

Artlgas F., Perez V., Alvarez E. Plndolol induces a rapid improvement of depresssed patients treated with serotonin reuptake inhibitors // Arch. Gen. Psychiatry. 1994. V. 61. P. 248-257.

Baton R., Ontz A., Pohl R. et al. Heart rate and blood pressure during pla­cebo-associated panic attack // Psychosomatic Medicine. 1988. V. 50. P. 434-438.

Ban T. A., Ray O. S. A History of CINP. Brentwood. J. M. Productions. 1996, 457 p.

Baraldi P., Magnavacchi P., Mat toll G. II placebo nella terapia dell'angina pectoris // Minerva Cardioangiologica. 1984. V. 23. N. 3. P. 137-140.

Barry P. P. Iatrogenic disorders in the elderly: Preventive techniques // Geriatrics. 1986. V. 41. P. 42-47.

Baumann U. Zum Placebo-Konzept in der Psychotherapie // Das Placebo-Problem / Eds. H. Hippius. et al. Stuttgart: Gustav Fischer Verlag, 1986. S. 97-105.

Beck F. M. Placebos in dentistry: their profound potential effects // J. of Amer. Dental Ass. 1977. V. 95. No. 6. P. 1122-1126.

Becker M., Maiman L. A. Strategies for enhancing patient compliance // J. Commun. Health. 1980. V. 6. P. 113-117.

Beecher H. K. Increased stress and effectiveness of placebo and «active» drugs // Science. 1960. V. 132. P. 91

Beecher H. K. Surgery as placebo // JAMA. 1961. V. 176. P. 1102-1107.

Benkert O., Maier W. The necessity of placebo application in psychotropic drugs trials // Pharmacopsychiatry. 1990. V. 23. No. 5. P. 203-205.

Benson H., Epstein M. D. The placebo effect. A neglected asset in the care of patient // JAMA. 1975. V. 232. P. 1225-1227.

Benson H., Friedman R. Harnessing the power of placebo effect and re­naming it «Remembered wellness» // Ann. Rev. Med.: Selected Topics Clin. Sci. 1996. V. 47. P. 193-199.

Berger F. M., Potterbied J. The effect of antianxiety tranquillizers on the behavior of normal persons // The Psychopharmacology of the normal human / Eds. W. O. Evans, N. S. Kline. 1969. Springfield: Charles С Thomas, P. 38-113.

Bienenfeld L. et al. The placebo effect in cardiovascular disease // Amer. Heart J. 1996. V. 132. P. 1207-1221.

Billingsley K. D., Waehler C. A., Hardin 8. 1. Stability of optimism and choice of coping strategy // Perceptual and Motor Skills. 1993. V. 76. No. 1. P. 91-97.

Birren F. Color psychology and color therapy. N. Y.: University Books, 1969. 302 p.

Blanz M. Ethische und rechtliche Aspekte des Plazeboeinsatzes in Forsc-hung und Praxis // Fortschritte der Neurologie-Psychiatrie. 1990. Bd. 58. S. 167-174.

Boissel J. P., Meillard O., Perrin-Fayolle E. et al. Exemple d'un essai de phase IV impliquant de nombreux medecins et visant a repondre a une question scientifique // Therapie. 1996.

Bojanovsky J., Chlouphova K. A comparison of the therapeutic effect of meprobamate administered in its current appearance and as an un­known drug // Activ. Nerv. Super. (Praha). 1966. V. 8. N. 4. P. 440.

Bok S. The ethics of giving placebos // Sci. Amer. 1974. V. 231. P. 17-23.

Boleloucky Z. A contribution to the problems of placebo dependence: case report. Activitas Nervosa Superior (Praha). 1971. V. 13. N. 3. P. 190-191.

Bolger N. Coping as personality process: a prospective study // J. of Per­sonality and Social Psychology. 1990. V. 59. No. 3. P. 525-537.

Bosley C. M., Fosbury J. A, Cochrane G. M. The psychological factors as­sociated with compliance with treatment in asthma // European Respiratory J. 1995. V. 8. P. 899-904.

Плацебо и терапия

Bostrom H. Placebo — the forgotten drug // Scand. J. of work, environ­ment and health. 1997. V. 23. Suppl. 3. P. 53-58.

Boudwin J., Kline N. S. Use of reserpine in non-disturbed psychotics // Psychiat. Res. Rep. 1956. V. 4. P. 71-78.

Bourne H. R. Das Placebo — eine ungenugend verstandene und verpach-lassigte therapeutische Massnahme // Der Internist. 1972. S. 345 ff.

Brodie В. В. Some ideas on the mode of action of imipramine-type antide-pressants // The Scientific Basis of Drug Therapy in Psychiatry / Eds. J. Marks, С M. B. Pare. Oxford: Pergamon Press, 1965. P. 127-146.

Brody B. A. When are placebo-controlled trials no longer appropriate? // Controlled Clinical Trials. 1997. V. 18. P. 602-612.

Brody H. (Ed. ) Placebos and the. philosophy of medicine. Clinical, concep­tual and ethical issues / Chicago. The University of Chicago Press. 1980. 277 p.

Brown S., Goldman M., Inn A et al. Expectations of reinforcement from alcohol: their domain and relation to drinking patterns // J. Consult. Clin. Psychol. 1980. V. 48. P. 419-426.

Brown W. A Predictors of placebo response in depression // Psychophar-macol. Bull. 1988. V. 24. No. 1. P. 14-17.

Brown W. A Is light treatment a placebo? // Psychopharmacol. Bull. 1990. V. 26. P. 527-530.

Brown W. A Clinical features of depressed patients who do and do not improve with placebo // Psychiatry Res. 1992. V. 41. P. 203-214.

Brown W. A Placebo as a treatment for depression // Neuropsychophar-macology. 1994. V. 10. No. 4. P. 265-269.

Brown W. A The placebo effect // Scientific American. 1998. V. 278. P. 90-95.

Brown W. A, Dornseif В. E., Wernicke J. F. Placebo response in depres­sion: A search for predictors // Psychiatry Res. 1988. V. 26. P. 259-264.

Buckalew L. W., Coffield К. E. An investigation of drug expectance as a function of capsule color and size and preparation form // J. Clin. Psychopharmacol. 1982. V. 2. P. 245-248.

Buckalew W., Ross S., Starr B. J. Nonspecific factors in drug effects: Pla­cebo personality // Psychol. Rep. 1981. V. 48. P. 3-8.

Buguet A, Montmayeur A, Pigeau, Naitoh P. Modafinil, d amphetamine and placebo during 64 hours of sustained mental work. 2. Effects on two nights of recovery sleep // J. of Sleep Research. 1995. Vol. 4. No. 4. P. 229-242.

Carty M. A., Everitt D. E. Basic principles of prescribing for geriatric out­patients // Geriatrics. 1989. V. 44. No. 6. P. 85-98.

Chillot R. Homeopathy // Prevention. 1998, March. V. 50. No. 3. P. 106-111; 187-189.

Classen W., Feingold E. Use of placebos in medical practice // Pharma-copsychiat. 1985. V. 18. P. 131-132.

Cleophas T. J. -M. Clinical trials: specific problems with the use of a place­bo-control group // J. of Molecular Medicine. 1995. V. 73. No. 8. P. 421-424.

Clyde D. J. Self-rating // Drugs and Behavior / Eds. L. Uhr, J. G. Miller. N. Y.: Wiley, 1960. P. 583-597.

Cole J. The evaluation of the effectiveness of treatment in psychiatry // Psychopharmacology. Problems of evaluation / Eds. J. C. Cole, R. W. Gerard. Washington: Nat. Acad. of Sci., 1959. P. 92-107.

Collier J, Conclusion over use of placebos in clinical trials — Better guide­lines needed // Brit. Med. J. 1995. V. 311. No. 7009. P. 821.

Compliance with pharmacological treatment // (Editorial) Medicina (Bue­nos Aires). 1997. V. 7. N. 1. P. 111-113.

Conen D., Besch W., Dubach U. C. Berner U. Verstehen die Arzte ihre Pa-tienten? // Dtsch. Med. Wschr. 1986. Bd. 111. S. 51-55.

Литература

Conner» G., Maisto S. Effects of alcohol, instructions, and consumption

rate on motor performance // J. Stud. Alcohol. 1980. V. 41. P. 509-

517. Coper H. Warum sind sicher wirksame Arzneimittel nicht mehr sicher

wirksam? // Munch. Med. Wschr. 1985. Bd. 127. Nr. 49. S. 1123. Costa E. V. Compliance with antihypertensive treatment // Clinical and

experimental hypertension. 1996. V. 18. P. 463-472. Cox W. M., Blount J. P., Crowe P. A. et al. Diabetic patients' alcohol and

quality of life: relationships with prescribed treatment compliance among

older males // Alcoholism. 1996. V. 20. P. 327-331. Cramer J., Vachon L., Desforges C. et al. Dose frequency and dose interval

compliance with multiple antiepileptic medications during a controlled

clinical trial // Epilepsia. 1995. V. 36. P. 1111-1117. Crawford P., Chadwick D. A comparative study of progabide, valproate,

and placebo as add-on therapy in patients with refractory epilepsy //

J. Neurol. Neurosurg. Psychiatry. 1986. V. 49. P. 1251-1257. _ Crowell C. R., Hinson R. E., Siegel S. The role of conditioned drug respons­es in tolerance to the hypothermic effects of ethanol // Psychopharma-

cology. 1981. V. 73. P. 51-54. Dager S. R, Khan A., Cowley D. et al. Characteristics of placebo response

during long-term treatment of pain disorder // Psychopharmacol. Bull.

1990. V. 26. No. 3. P. 273-278. Dago P. L., Quithin F. M. Role of the placebo response in the treatment of

depressive disorders // CNS Drugs. 1995. V. 4. No. 5. P. 335-340. Davies C, Ralevski E., Kennedy S. H., Neitzert C. The role of personality

factors in the reporting of side effect complaints to moclobemide and

placebo: a study of healthy male and female volunteers // J. Clin.

Psychopharmacol. 1995. V. 15. No. 5. P. 347-352. De Craen A. J. et al. Is there a need to control placebo in placebo controlled

trials? // (Editorial). Heart. 1997. V. 77. P. 95-96. De Deyn P. P. et al. Placebos in clinical practice and research //

J. Med. Ethics. 1996. V. 22. P. 140-146 De Giacomo P., Silvestri A, Pierri G., Lefons E., Corfiati L., Tangorra F.

Research on the effects of psychodrugs on human interaction.

A theoretical/experimental approach // Acta psychiatr. scand. 1986.

V. 74. P. 417-424. Defons E., Corfiati L., Tangorra F. Research on the effects of psychodrugs

on human interaction. A theoretical/experimental approach // Acta

psychiatr. scand. 1986. V. 74. P. 417-424. De Leo D., Rocco P. L., Dello Buono, Valla Barra G. F. Grey mood: grey

colors // Lancet. 1989, Sept. 2. P. 573-574. Del Boca F. K., Kranzler H. R., Brown J. et al. Assessment of medication

compliance in alcoholics through UV light detection of a riboflavin

trascer // Alcoholism. 1996. V. 20. P. 1412-1417. Demyttenaere K. Compliance during treatment with antidepressants //

J. Eof Affective Disorders. 1997. V. 43. No. 1. P. 27-40. DiMascio A., Barrett J. Comparative effects of oxazepam in «high» and

«low» anxious student volunteers // Psychosomatics. 1965. V. 6.

P. 298-302. DiMascio A., Rinkel M. Personality and drugs. «Specific» and «Non-Spe-

cific» Influences on Drug Action // Specific and Non-Specific Factors

in Psychopharmacology / Ed. M. Rinkel. 1963. N. Y.: Philosophical

Library. P. 130-140. Dobrilla G., Scarpignato С Placebo and placebo effect: their impact on the

evaluation of drug response in patients // Digestive Diseases. 1994.

V. 12. No. 6. P. 368-377.

Double D. B. Placebo mania. Placebo controlled trials are needed to pro­vide data on effectiveness of active treatment (letter) // Brit. Med. J.

1996. V. 313. No. 7063. P. 1008-1009.

Плацебо и терапия

Downing R. W., Rickets К., King L., Rickets L. A. Factors influencing dos­age deviation and attrition in placebo treated neurotic outpatients // J. Psychiat. Res. 1975. V. 12. P. 239-256.

Dow son D. I., Lewith G. Т., Machin D. The effects of acupuncture versus placebo in the treatment of headache // Pain. 1985. V. 21. P. 35-42.

Doyle A. E. Response to placebo treatment in hypertension. Hyperten­sion. 1983. V. 5. No. 5. P. 1113-1114.

Drory V. E., Korczyn A. D. Apparent placebo effect in epilepsy // New Trends Clin. Psychopharmacol. 1991. V. 5. No. 2. P. 49-56. Цит. по РЖ 04. Биология. 1992. 4. Т. З. 199.

Duburg G. O. Compliance therapy in psychotic patients. Authors are wrong to compare treatment with no treatment // Brit. Med. J. 1996. V. 312. P. 1302.

Eastman C. /. What the placebo literature can tell us about light therapy for SAD // Psychopharmacol. Bull. 1990. V. 26. P. 495-504.

Elizaga J., Friedland J. S. Monitoring compliance with antituberculosis treatment by detection of isoniazid in urine // Lancet. 1997. V. 350. No. 9086. P. 1225-1226.

Ellgring H. Nonverbal expression of psychological states in psychiatric patients // Eur. Arch. Psychiatr. Neurol. Sci. 1986. V. 236. P. 31-34.

Epstein J. B. Understanding placebos in dentistry // J. of Amer. Dental Ass. 1984. V. 109. No. 1. P. 71-74.

Ernst E., Herxheimer A. The power of placebo — Let's use it to help us as much as possible // Brit. Med. J. 1996. V. 313. No. 7072. Dec. 21. P. 1569-1570.

Ernst E., Resch K. L. Concept of true and perceived placebo effects // Brit. Med. J. 1995. V. 311. No. 7004. P. 551-553.

Esse S. Placebo reactions and spontaneous rhythms in psychotherapy // Arch. Gen. Psychiatry. 1964. V. 10. No. 5. P. 497-505.

Evans L., Spelman M. The problem of non-compliance with drug therapy // Drugs. 1983. V. 25. P. 63-66.

Fedder D. O. Managing medication and compliance: physician-pharmacist-patient interaction // J. Amer. Geriat. Soc. 1982. V. 30. S. 113.

Feldman D. E. Non-drug parameters of psychopharmacology. The role of the physician // specific and non-specific factors in psychopharmacol­ogy / Ed. M. Rinkel. N. Y.: Philosophical Library, 1963. P. 149-158.

Fenton W. S., Blyler C. R., Heinssen R. K. Determinants of medication com­pliance in schizophrenia: empirical and clinical findings // Schizophre­nia Bull. 1997. V. 23. No. 4. P. 637-652.

Fillmore M., Vogel-Sprott M. Expected effect of caffeine on motor per­formance predicts the type of response to placebo // Psychopharmacol­ogy. 1992. V. 106. P. 209-214.

Fischer H. K., Dlin В. Af. The dynamics of placebo therapy: a clinical study. Amer. J. Med. Sci. 1956. V. 232. P. 504-512.

Folli G. et al. Placebo effect in the treatment of angina pectoris // Acta Cardiologica. 1978. V. 33. N. 4. P. 231-239.

Fossey Af. D.. Lydiard R. B. Placebo response in patients with anxiety disor­ders // The treatment of anxiety. Handbook of anxiety / Eds. R. Noyes, M. Roth, G. Burrows. Amsterdam: Elsevier, 1990. P. 27-56.

Frank D. R. Psychological theories of the effects of placebos with special consideration for the contribution theory // Pharmacopsychiatry. 1986. V. 19. P. 337-338.

Frank J. D., Gliedman L. #., Imber S. D., Nash E. H., Stone A. R. Why patients leave psychotherapy // AMA Arch. Neurol. Psychiat. 1957. V. 77. P. 283-

Gartner M. A. Selected personality differences between placebo reactors and non-reactors // J. Amer. Osteopath. Ass. 1961. V. 60. P. 377-378.

Литература                                                             213

Gauler Т. С, Weihrauch Т. R. Placebo — an effective and harmless drug? // Naunyn-Schmiedeberg's Arhiv of Pharmacology. 1996. V. 354. Suppl. 1 (Abstracts of the Autumn Meeting of the Deutsche Gesellschaft fiir experimentalle und klinische Pharmakologie und Toxikologie. P. 24.

Geerts E., Bouhuys N. Multi-level prediction of short-term outcome of de­pression: non-verbal interpersonal processes, cognitions and personal­ity traits // Psychiatry Research. 1998. V. 79. No. 1. P. 59-73.

Gillin J. C. et al. No antidepressant effects of biperiden compared with placebo in depression: a double-blind 6-week clinical trial // Psychiat­ric Research. 1995. V. 58. No. 2. P. 99-106.

Girvin В., Byrne A, Kiny D. J., Wilson-Davis K., Johnston G. D. An assess­ment of erythrocyte lithium concentration as a measure of patient compliance // Human Psychopharmacology — clinical and experimen­tal. 1996. V. 11. No. 6. P. 491-496.

Glassman J. N. The psychodynamics of prescribing and receiving medi­cation // Psychiatric Times. 1998, May. P. 33-35.

Glaudin V., Smith W. Т., Ferguson J. M. et al. Discriminating placebo and drug in generalized anxiety disorder (GAD) trials: single versus mul­tiple clinical raters // Psychopharmacol. Bull. 1994. V. 30. P. 101.

Gliedman L. H., Nash E. H., Imber S. D. et al. Reduction of symptoms by pharmacologically inert substances and by short-term psychothera­py // Arch. Neurol. Psychiatry. 1958. V. 79. P. 345-351.

Gotzsche P. C. Placebo effects — Concept of placebo should be discard­ed // Brit. Med. J. 1995. Vol. 311. No. 7020. Dec. 16. P. 1640.

Gracely R. H., Dubner R., Wolskee P. J. et al. Placebo and naloxone can alter post-surgical pain by separate mechanisms // Nature. 1983. V. 306. P. 264-265.

Gray G., Flynn P. A survey of placebo use in general hospital // General Hospital Psychiatry. 1981. V. 3. No. 3. P. 199-203.

Greenberg R. P., Fischer S. Examining antidepressant effectiveness: find­ings, ambiguities, and some vexing puzzles. The Limits of Biological Treatments for Psychological Distress: Comparisons wirh Psychother­apy and Placebo / Eds. S. Fischer, R. P. Greenberg Lawrence Erl-baum Associates. Hillsdale, N. Y., 1989. P. 1-37.

Gross F. Placebo — das universalle Medikament. Mainz. MPS. 1984. 134 S.

Grunbaum A. The placebo concept in medicine and psychiatry // Psychol. Med. 1986. V. 16. P. 19-38.

Haas H. et al. Das Placebo-Problem // Fortschritte der Arzneimittelfor-schung / Ed. E. Jucker. 1959. Bd. 1. S. 279.

Hafer H. Angst als Chance und als Krankheit // Fundamenta Psychiat-rica. 1987. V. 1.

Haimovic I. C, Beresford H. R. Dexamethasone is not superior to place­bo for treating lumbosacral radicular pain // Neurology. 1986. V. 36. No. 12. P. 1593-1594.

Harrison W. et al. Is loss of antidepressant effect during continuation therapy related to placebo effect? // Psychopharmacol. Bull. 1988. V. 24. P. 9-13.

Hart F. D. Placebos used not to be used in studies // Brit. Med. J. 1995. V. 311. No. 7020. P. 1641.

Hart noil R. Non-pharmacological factors in drug abuse // Behavioral Phar­macol. 1990. V. 1. P. 375-384.

Hayes-Bautista D. F. Modifying the treatment: patient compliance, patient control and medical care // Soc. Sci. Med. 1976. V. 10. P. 233-235.

Heeg W., Deutsche K. F., Deutsche E. The placebo effect // Eur. J. Nu­clear Medicine. 1997. V. 24. P. 1433-1444.

Henlnger G., DiMascio A., Klerman G. L. Personality factors in variabil­ity of response to phenothiazines // Amer. J. Psychiatry. 1965. V. 121. P. 1091-1094.

Плацебо и терапия

Негг A. The role of opioid peptides in placebo-induced effects // Phar-macopsychiat. 1986. V. 19. P. 339-340.

Hesbacher P. Т., Rickels K., Hutchison I. et al. Setting, patient, and doc­tor effects on drug response in neurotic patients: II Differential im­provement // Psychopharmacologia. 1970. V. 18. P. 209-226.

Hese R. Т., Chmurska M. Porownanie wynikow leczenia chorych na nerv-ice lekami psychotropoowymi i placebo // Psychiatria Polska. 1982. V. 16. N. 4. P. 267-272.

Heszen-Klemens I. Patients' noncompliance and how doctors manage this // Clin. Sci. Med. 1987. V. 24. No. 5. P. 409-416.

Hill M. N.. Niller N. Y. Compliance enhancement: A call for multidisci-plinary team approaches // Circulation. 1996. V. 93. P. 4-6.

Hippius H. et al. (Eds. ) Das Placebo-Problem. Stuttgart: Fischer-Verlag, 1986. S. 151

Hollon S. D., Beck A. T. Psychotherapy and drug therapy: comparisons and combinations // Handbook of Psychotherapy and behavior change: an empirical analysis / Eds. S. L. Garfield, A. E. Bergin. 2nd edition. N. Y.: Wiley, 1978. P. 64-64.

Hollon S. D., De Rubeis R. J. Placebo-psychotherapy combinations: inap­propriate representations of psychotherapy in drug-pscyhotherapy com­parative trials // Psychological Bull. 1981. V. 90. P. 467-477.

Home J. A., Reyner t. A. Counteracting driver sleepness: Effects of nap­ping, caffeine, and placebo // Psychophysiology. 1996. V. 33. No. 8. P. 306-310.

Hubin P., Servais J. Etude typologique du placebo-reacteur // Psychop­harmacologia. 1965. V. 7. No. 4. P. 235-255.

Hyland J. Integrating psychotherapy and pharmacotherapy // Bull. Men-ninger Clinic. 1991. V. 55. P. 205-215

Illhardt F. J. Placebo und Ethik // Z. Allgem. Med. 1988. Bd. 64. S. 279-283.

Isohanni M. Psychotropic drugs in the therapeutic community // Psychi­atria fennica. Intern. Edition. 1982. P. 175-186.

Jacobs K. W., Nordan F. M. Classification of placebo drugs: effect of color // Perceptual and Motor Skills. 1979. V. 49. P. 367-372.

Janke W. Consistency of response to placebo with different instructions // Pharmacopsychiat. 1986. V. 19. P. 345-346.

Janke W. Untersuchungen zur Placeboreaktivitflt: Vorheragbarkeit der Reaktion gesunder Personen auf Placebo mit Stimulans-Instruktion. «Das Placebo-Problem» / Herausgegeben H. Hippius. et al. Stuttgart; N. Y.: Fischer Verlag, 1986. S. 151-171.

Jensen M. P., Karoly P. Motivation and expectancy factors in symptom perception: a laboratory study of the placebo effect // Psychosomatic medicine. 1991. V. 53. P. 144-152.

Joyce C. R. B. The personality of healthy reactors and nonreactors to dum­my treatment // Neuropsychopharmacology / Eds. P. B. Bradley, P. Deniker P, С N. Radouco-Thomas. Y.: Elsevier, 1959. P. 448-452.

Karasu T. Psychotherapy and pharmacotherapy: toward an integrated model // Amer. J. Psychotherapy. 1982. V. 139. P. 1102-113.

Karson C. N. et al. Clonazepam treatment of chronic schizophrenia: nega­tive results in a double-blind placebo-controlled trial // Amer. J. Psy­chiatry. 1982. V. 139. No. 12. P. 1627-1628/

Khan A. et al. Chronicity of depressive episode in relation to antidepres-sant-placebo response // Neuropsychopharmacology. 1991. V. 4. No. 2. P. 125-130.

Kienle G. S. et al. Placebo effect and placebo concept: a critical methodo­logical and conceptual analysis of reports on the magnitude of the placebo effect // Altern. Ther. Health Med. 1996. V. 2. P. 39-54.

Kirsch I. Response expectancy as a determinant of experience and behav­ior // American Psychologist. 1985. V. 40. P. 1189-1202.

Литература                                                             215

Kirsch I., Weixel L. J. Double-blind versus deceptive administration of a placebo // Behavioral Neuroscience. 1988. V. 102. P. 319-323.

Klerman G. L. Scientific and ethical considerations in the use of placebo controls in clinical trials in psychopharmacology // Psychopharmacol. Bull. 1986. V. 22. No. 1. P. 25-29.

Klerman G. L., Di Mascio A., Rinkel M., Greenblatt M. The influence of specific personality patterns on the reactions to phrenotropic drugs // Biological Psychiatry / Ed. J. Masserman. N. Y.: Grune, 1959. V. 1. P. 224-226.

Kroneerg G. Placebotherapie. XIII. Medicenale. Iserlohn. 1982. 468 s.

Kuhn R. bber die Behandlung depressiver Zustande mit einem iminodiben-zylderivat (G 22355) // Schweiz. Med. Wschr. 1957. Bd. 87. S. 1135.

Kuhn R. The treatment of depressive states with G 22355 (imipramine hydrochloride) // Amer. J. Psychiatry. 1958. V. 115. P. 459-464.

Kuhn R. History and future of antidepressants // The Rise of Psychophar­macology / Ed. T. A. Ban, D. Healy, E. Shorter. Budapest: Animula, 1998. P. 76-77.

Kurland A. A. The drug placebo: its psychodynamic and conditioned reflex action // Behav. Sci. 1957. V. 2. P. 101-110.

Kuschinsky G. Wirkvmgen und Indikationen von Placebo // Dtsch. Arzte-bl. 1975. Bd. 72. S. 663-666.

Kashner M. G., Sher K. J. Anxiety and drinking behavior: moderating ef­fects of alcohol-related expectancies // Pharmacol. Biochem. Behav. 1992. V. 16. Suppl. P. 378.

Lange H. U. Zur Praxis der Plazebobehandlung in einer psychiatrischen Klinik // Psychiatrische Praxis. 1981. Bd. 8. Nr. 4. S. 147-151.

Langer G. Placebo: Jenseits von «Schein» und «Storgrosse» // Wien. klin. Wochenschr. 1987. Bd. 99. Suppl. 175. S. 13/

Lapin I. P. Kynurenines as probable participants of depression // Pharma-kopsychiatrie-Neuropsychopharmakologie. 1973. V. 6. P. 273-279.

Lapin I. P. Only controls: effect of handling, sham injection and intraperito-neal injection of saline on behavior of mice in an elevated plus-maze // J. Pharmacol, and Toxicol. Methods. 1995. V. 34. No. 2. P. 73-77.

Lapin I. P. Lowered serotonin uptake in blood platelets (SU) in alcoholic patients. Is it specific for alcoholism? Does it appear before or during the disease? // Alcohol and alcoholism. 1997. V. 32. P. 383.

Lapin I. P. Three foundation stones of the laboratory of psychopharmacol­ogy // The Rise of Psychopharmacology and the story of CINP / Ed. by T. A. Ban, D. Healy, E. Shorter. Budapest: Animula, 1998. P. 323-329.

Lapin I. P., Oxenkrug G. F. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect // Lan­cet. 1969. V. 1. P. 132-136.

Lasagna L. Placebos // Sci. Amer. 1955. V. 193. P. 68-71.

Lasagna L. The relation of drug-induced changes to personality // Specif­ic and Non-specific Factors in Psychopharmacology / Ed. M. Rinkel. N. Y.: Philosophical Library, 1963. P. 114-129.

Lasagna L., Laties V. G., Dohan L. L. Further studies on the «pharmacolo­gy» of placebo administration // J. Clin. Invest. 1958. V. 37. P. 533-537.

Laurinaitis E. Ethical issues in the post-soviet psychiatry and psychother­apy — implications for research // The Synthesis between Psychophar­macology and Psychotherapy. Abstracts of the WPA Thematic Confer­ence (Jerusalem, Israel, Nov. 16-21, 1997). P. 12.

Lawrence D. R. Clinical pharmacology // Edinburgh; London; N. Y.: Church­ill Livingstone, 1973. 356 p.

Lazarus R. S., Folkman S. Coping and adaptation. The Handbook of Be­havioral Medicine / Ed. W. D. Gentry. N. Y.: Guilford, 1984. P. 282-325.

Плацебо и терапия

Leber P. The placebo control in clinical trials (a view from the FDA) // Psychopharm. Bull. 1986. V. 22. No. 1. P. 30-32.

Leder S., Bekarewicz В., Bigo В., Kosewska A. Proby analyzy czynnikow krsztaltujancych efekt placebo // Biul. Inst. Psyhoneurol (Warszawa). 1972. V. 3. S. 87-95.

Lehmann E. D., Hopkins K. D., Gosling R. G. Multiple definitions of «com­pliance» // Clinical Science. 1996. V. 90. P. 433-435.

Lehmann H. E., Knight D. A. Placebo proneness and placebo resistance of different psychological functions // Psychiat. Quat. 1960. V. 3. P. 505-516.

Leonhard K. Der menschliche Ausdruck // Johann Ambrosius Barth. Leip­zig, 1968. 320 s.



  

© helpiks.su При использовании или копировании материалов прямая ссылка на сайт обязательна.